Kaelin, William

Publication with MATCHING institution:

Kaelin W, Ratcliffe PJ, Semenza GL (2016) Pathways for Oxygen Regulation and Homeostasis: The 2016 Albert Lasker Basic
Medical Research Award. None. [IF=None, Cited=25, 27622845].
Kaelin W (2017) Climate Change: What Would Lincoln Do? None. [IF=None, Cited=0, 28810027].
Kaelin W (1999) Functions of the retinoblastoma protein. BioEssays. [IF=0.818, Cited=121, 10517868].
Kaelin W (2009) Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer. [IF=2.097,
Cited=76, 19402056].
Kaelin W, Pallas DC, DeCaprio JA, ..., Livingston DM (1991) Identification of cellular proteins that can interact
specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell. [IF=8.479, Cited=345, 1825028].
Kaelin W, Krek W, Sellers WR, ..., Blanar MA (1992) Expression cloning of a cDNA encoding a retinoblastoma-binding
protein with E2F-like properties. Cell. [IF=8.479, Cited=515, 1638635].
Kaelin W (2005) The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochemical and Biophysical
Research Communications. [IF=0.643, Cited=134, 16153592].
Kaelin W (2014) DisABLing kidney cancers caused by fumarate hydratase mutations. Cancer Cell. [IF=5.274, Cited=2, 25490441].
Shi DD, Savani MR, Levitt M, ..., McBrayer SK (2022) De novo pyrimidine synthesis is a targetable vulnerability in IDH
mutant glioma. Cancer Cell. [IF=5.274, Cited=27, 35985343].
Kaelin W (2008) Kidney cancer: now available in a new flavor. Cancer Cell. [IF=5.274, Cited=16, 19061830].
Kaelin W (2009) SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling. Cancer Cell. [IF=5.274,
Cited=46, 19732718].
Li L, Shen C, Nakamura E, ..., Kaelin W (2013) SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
Cancer Cell. [IF=5.274, Cited=97, 24332042].
Lu G, Zhang Q, Huang Y, ..., Kaelin W (2014) Phosphorylation of ETS1 by Src family kinases prevents its recognition by
the COP1 tumor suppressor. Cancer Cell. [IF=5.274, Cited=50, 25117710].
Kaelin W, Kaelin WG, McKnight SL (2013) Influence of metabolism on epigenetics and disease. Cell. [IF=8.479, Cited=499, 23540690].
Olenchock BA, Moslehi J, Baik AH, ..., Kaelin W (2016) EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for
Remote Ischemic Protection. Cell. [IF=8.479, Cited=73, 26919427].
Briggs KJ, Koivunen P, Cao S, ..., Kaelin W (2016) Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1
Senses Cysteine. Cell. [IF=8.479, Cited=134, 27368101].
McBrayer SK, Mayers JR, DiNatale GJ, ..., Kaelin W (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs
Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. [IF=8.479, Cited=176, 30220459].
Kaelin W (2021) David M. Livingston (1941-2021). Cell. [IF=8.479, Cited=1, 34890547].
Lampson BL, Ramίrez AS, Baro M, ..., Kaelin W (2024) Positive selection CRISPR screens reveal a druggable pocket in an
oligosaccharyltransferase required for inflammatory signaling to NF-κB. Cell. [IF=8.479, Cited=0, 38670073].
Kaelin W (2005) ROS: really involved in oxygen sensing. Cell Metabolism. [IF=4.686, Cited=98, 16054083].
Harris IS, Endress JE, Coloff JL, ..., Brugge JS (2019) Deubiquitinases Maintain Protein Homeostasis and Survival of
Cancer Cells upon Glutathione Depletion. None. [IF=None, Cited=76, 30799286].
Shirole NH, Kaelin W (2023) von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma
Biology. Hematology/Oncology Clinics of North America. [IF=1.055, Cited=2, 37270382].
German NJ, Yoon H, Yusuf RZ, ..., Haigis MC (2016) PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid
Oxidation via Deactivation of ACC2. Molecular Cell. [IF=2.773, Cited=90, 27635760].
Ivan M, Kaelin W (2017) The EGLN-HIF O₂-Sensing System: Multiple Inputs and Feedbacks. Molecular Cell.
[IF=2.773, Cited=124, 28622522].
Shi DD, Lee JH, Wang AC, ..., McBrayer SK (2023) Protocol to establish a genetically engineered mouse model of
IDH1-mutant astrocytoma. STAR Protocols. [IF=0.357, Cited=1, 37149859].
Cho H, Du X, Rizzi JP, ..., Kaelin W (2016) On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer
models. Nature. [IF=11.591, Cited=250, 27595393].
Lorenzo FR, Huff C, Myllymäki M, ..., Prchal JT (2014) A genetic mechanism for Tibetan high-altitude adaptation. Nature
Genetics. [IF=6.89, Cited=219, 25129147].
Bass AJ, Lawrence MS, Brace LE, ..., Meyerson M (2011) Genomic sequencing of colorectal adenocarcinomas identifies a
recurrent VTI1A-TCF7L2 fusion. Nature Genetics. [IF=6.89, Cited=211, 21892161].
Kaelin W (2017) Common pitfalls in preclinical cancer target validation. Nature Reviews Cancer. [IF=10.357, Cited=85, 28524181].
Kaelin W (2002) Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer. [IF=10.357, Cited=485, 12209156].
Liu J, Peng Y, Shi L, ..., Wei W (2021) Author Correction: Skp2 dictates cell cycle-dependent metabolic oscillation
between glycolysis and TCA cycle. Cell Research. [IF=3.826, Cited=0, 32859994].
Liu J, Peng Y, Shi L, ..., Wei W (2020) Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and
TCA cycle. Cell Research. [IF=3.826, Cited=38, 32669607].
Zhang T, Xu D, Liu J, ..., Wei W (2023) Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1
to promote necroptosis and inflammation. Nature Cell Biology. [IF=3.908, Cited=7, 37400498].
Losman JA, Koivunen P, Kaelin W (2020) 2-Oxoglutarate-dependent dioxygenases in cancer. Nature Reviews Cancer.
[IF=10.357, Cited=85, 33087883].
Choueiri TK, Kaelin W (2020) Targeting the HIF2-VEGF axis in renal cell carcinoma. Nature Medicine. [IF=11.877,
Cited=192, 33020645].
Kaelin W (1999) The p53 gene family. Oncogene. [IF=1.523, Cited=115, 10618710].
Kaelin W, Iliopoulos O, Lonergan KM, Ohh M (1998) Functions of the von Hippel-Lindau tumour suppressor protein. Journal
of Internal Medicine. [IF=2.659, Cited=30, 9681855].
Kamihara J, Hamilton KV, Pollard JA, ..., DuBois SG (2021) Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang
Syndrome. New England Journal of Medicine. [IF=17.194, Cited=28, 34818480].
Suhara T, Hishiki T, Kasahara M, ..., Minamishima YA (2015) Inhibition of the oxygen sensor PHD2 in the liver improves
survival in lactic acidosis by activating the Cori cycle. Proceedings of the National Academy of Sciences of the United
States of America. [IF=2.765, Cited=26, 26324945].
Zhang C, Li X, Adelmant G, ..., Kaelin W (2015) Peptidic degron in EID1 is recognized by an SCF E3 ligase complex
containing the orphan F-box protein FBXO21. Proceedings of the National Academy of Sciences of the United States of
America. [IF=2.765, Cited=13, 26631746].
Gao W, Li W, Xiao T, ..., Kaelin W (2017) Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in
VHL-/- clear cell renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America.
[IF=2.765, Cited=89, 28082722].
McBrayer SK, Olenchock BA, DiNatale GJ, ..., Kaelin W (2018) Autochthonous tumors driven by Rb1 loss have an
ongoing requirement for the RBP2 histone demethylase. Proceedings of the National Academy of Sciences of the United
States of America. [IF=2.765, Cited=8, 29610306].
Li AG, Murphy EC, Culhane AC, ..., Livingston DM (2018) BRCA1-IRIS promotes human tumor progression through PTEN
blockade and HIF-1α activation. Proceedings of the National Academy of Sciences of the United States of America.
[IF=2.765, Cited=11, 30254159].
Koduri V, McBrayer SK, Liberzon E, ..., Kaelin W (2019) Peptidic degron for IMiD-induced degradation of heterologous
proteins. Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765, Cited=21, 30683719].
Li S, Rodriguez J, Li W, ..., Schlisio S (2019) EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to
pheochromocytoma pathogenesis and chemotherapy resistance. Proceedings of the National Academy of Sciences of the United
States of America. [IF=2.765, Cited=11, 31375625].
Stransky LA, Vigeant SM, Huang B, ..., Kaelin W (2022) Sensitivity of VHL mutant kidney cancers to HIF2
inhibitors does not require an intact p53 pathway. Proceedings of the National Academy of Sciences of the United States
of America. [IF=2.765, Cited=12, 35357972].
Flemington EK, Speck SH, Kaelin W (1993) E2F-1-mediated transactivation is inhibited by complex formation with the
retinoblastoma susceptibility gene product. Proceedings of the National Academy of Sciences of the United States of
America. [IF=2.765, Cited=202, 8346196].
Qin XQ, Livingston DM, Kaelin W, Adams PD (1994) Deregulated transcription factor E2F-1 expression leads to S-phase
entry and p53-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America.
[IF=2.765, Cited=425, 7971984].
Sellers WR, Rodgers JW, Kaelin W (1995) A potent transrepression domain in the retinoblastoma protein induces a cell
cycle arrest when bound to E2F sites. Proceedings of the National Academy of Sciences of the United States of America.
[IF=2.765, Cited=155, 8524800].
Iliopoulos O, Levy AP, Jiang C, ..., Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von
Hippel-Lindau protein. Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765,
Cited=467, 8855223].
Chen YN, Sharma SK, Ramsey TM, ..., Kaelin W (1999) Selective killing of transformed cells by cyclin/cyclin-dependent
kinase 2 antagonists. Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765,
Cited=175, 10200261].
Laukka T, Mariani CJ, Ihantola T, ..., Koivunen P (2015) Fumarate and Succinate Regulate Expression of Hypoxia-inducible
Genes via TET Enzymes. Journal of Biological Chemistry. [IF=1.122, Cited=161, 26703470].
Kim TY, Kaelin W (2001) Differential control of transcription by DNA-bound cyclins. Molecular Biology of the Cell.
[IF=0.848, Cited=12, 11452014].
Choueiri TK, Pal SK, McDermott DF, ..., Dutcher JP (2014) A phase I study of cabozantinib (XL184) in patients with renal
cell cancer. Annals of Oncology. [IF=8.208, Cited=92, 24827131].
Kaelin W (1999) The emerging p53 gene family. Journal of the National Cancer Institute. [IF=3.144, Cited=91, 10203277].
Miller JJ, Gonzalez Castro LN, McBrayer S, ..., Wen PY (2023) Isocitrate dehydrogenase (IDH) mutant gliomas: A Society
for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-Oncology. [IF=4.329,
Cited=40, 36239925].
Shi DD, Kaelin W (2023) The INDIGO trial: Precision medicine finally comes to glioma. Neuro-Oncology. [IF=4.329,
Cited=0, 37698505].
Kaelin W (2003) The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. Journal of the American Society of
Nephrology : JASN. [IF=2.771, Cited=72, 14569079].
Kaelin W (2002) How oxygen makes its presence felt. Genes and Development. [IF=1.985, Cited=93, 12080083].
Zheng X, Zhai B, Koivunen P, ..., Zhang Q (2014) Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its
interaction with the USP9x deubiquitinase. Genes and Development. [IF=1.985, Cited=85, 24990963].
Oser MG, Sabet AH, Gao W, ..., Kaelin W (2019) The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain
neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes and Development. [IF=1.985,
Cited=54, 31727771].
Kaelin W (2011) Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-
dependent dioxygenases. Cold Spring Harbor Symposia on Quantitative Biology. [IF=0.889, Cited=114, 22089927].
Cho H, Kaelin W (2016) Targeting HIF2 in Clear Cell Renal Cell Carcinoma. Cold Spring Harbor Symposia on Quantitative
Biology. [IF=0.889, Cited=32, 27932568].
Kaelin W (1997) Alterations in G1/S cell-cycle control contributing to carcinogenesis. Annals of the New York Academy of
Sciences. [IF=1.878, Cited=9, 9616737].
Kaelin W (2010) New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Annals of
the New York Academy of Sciences. [IF=1.878, Cited=7, 20973793].
Cable J, Finley L, Tu BP, ..., Kaelin W (2019) Leveraging insights into cancer metabolism-a symposium report. Annals of
the New York Academy of Sciences. [IF=1.878, Cited=2, 31792987].
Koduri V, Duplaquet L, Lampson BL, ..., Kaelin W (2021) Targeting oncoproteins with a positive selection assay for
protein degraders. Science advances. [IF=2.861, Cited=12, 33547076].
Min JH, Yang H, Ivan M, ..., Pavletich NP (2002) Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in
signaling. Science. [IF=7.729, Cited=425, 12004076].
Minamishima YA, Kaelin W (2010) Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. [IF=7.729,
Cited=111, 20651146].
Kaelin W (2012) Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science. [IF=7.729,
Cited=108, 22837515].
Losman JA, Looper RE, Koivunen P, ..., Kaelin W (2013) (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis
and its effects are reversible. Science. [IF=7.729, Cited=456, 23393090].
Lu G, Middleton RE, Sun H, ..., Kaelin W (2013) The myeloma drug lenalidomide promotes the cereblon-dependent
destruction of Ikaros proteins. Science. [IF=7.729, Cited=753, 24292623].
Kaelin W (1998) Another p53 Doppelgänger? Science. [IF=7.729, Cited=14, 9679018].
Stebbins CE, Kaelin W, Pavletich NP (1999) Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor
suppressor function. Science. [IF=7.729, Cited=496, 10205047].
Kamura T, Koepp DM, Conrad MN, ..., Conaway JW (1999) Rbx1, a component of the VHL tumor suppressor complex and SCF
ubiquitin ligase. Science. [IF=7.729, Cited=487, 10213691].
Kibel A, Iliopoulos O, DeCaprio JA, Kaelin W (1995) Binding of the von Hippel-Lindau tumor suppressor protein to Elongin
B and C. Science. [IF=7.729, Cited=378, 7660130].
Wang CY, Petryniak B, Thompson CB, ..., Leiden JM (1993) Regulation of the Ets-related transcription factor Elf-1 by
binding to the retinoblastoma protein. Science. [IF=7.729, Cited=117, 8493578].
Guo J, Chakraborty AA, Liu P, ..., Wei W (2016) pVHL suppresses kinase activity of Akt in a proline-hydroxylation-
dependent manner. Science. [IF=7.729, Cited=127, 27563096].
Miao D, Margolis CA, Gao W, ..., Van Allen EM (2018) Genomic correlates of response to immune checkpoint therapies in
clear cell renal cell carcinoma. Science. [IF=7.729, Cited=634, 29301960].
Zhang J, Wu T, Simon J, ..., Zhang Q (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell
renal cell carcinoma. Science. [IF=7.729, Cited=111, 30026228].
Chakraborty AA, Laukka T, Myllykoski M, ..., Kaelin W (2019) Histone demethylase KDM6A directly senses oxygen to control
chromatin and cell fate. Science. [IF=7.729, Cited=184, 30872525].
Wyant GA, Yu W, Doulamis IP, ..., Kaelin W (2022) Mitochondrial remodeling and ischemic protection by G protein-coupled
receptor 35 agonists. Science. [IF=7.729, Cited=35, 35926043].
Nicholson HE, Tariq Z, Housden BE, ..., Kaelin W (2019) HIF-independent synthetic lethality between CDK4/6 inhibition
and VHL loss across species. Science Signaling. [IF=1.6, Cited=28, 31575731].
Chakraborty AA, Nakamura E, Qi J, ..., Kaelin W (2017) HIF activation causes synthetic lethality between the VHL
tumor suppressor and the EZH1 histone methyltransferase. Science Translational Medicine. [IF=2.778, Cited=24, 28701475].
Kaelin W (2004) Gleevec: prototype or outlier? None. [IF=None, Cited=8, 15039489].
Li L, Zhang L, Zhang X, ..., Kaelin W (2007) Hypoxia-inducible factor linked to differential kidney cancer risk seen
with type 2A and type 2B VHL mutations. Molecular and Cellular Biology. [IF=1.026, Cited=74, 17526729].
Minamishima YA, Moslehi J, Padera RF, ..., Kaelin W (2009) A feedback loop involving the Phd3 prolyl hydroxylase tunes
the mammalian hypoxic response in vivo. Molecular and Cellular Biology. [IF=1.026, Cited=102, 19720742].
Yan Q, Bartz S, Mao M, ..., Kaelin W (2007) The hypoxia-inducible factor 2alpha N-terminal and C-terminal
transactivation domains cooperate to promote renal tumorigenesis in vivo. Molecular and Cellular Biology. [IF=1.026,
Cited=134, 17220275].
Qin XQ, Livingston DM, Ewen M, ..., Kaelin W (1995) The transcription factor E2F-1 is a downstream target of RB action.
Molecular and Cellular Biology. [IF=1.026, Cited=107, 7823942].
Adams PD, Sellers WR, Sharma SK, ..., Kaelin W (1996) Identification of a cyclin-cdk2 recognition motif present in
substrates and p21-like cyclin-dependent kinase inhibitors. Molecular and Cellular Biology. [IF=1.026, Cited=232, 8943316].
Marin MC, Jost CA, Irwin MS, ..., Kaelin W (1998) Viral oncoproteins discriminate between p53 and the p53 homolog p73.
Molecular and Cellular Biology. [IF=1.026, Cited=115, 9774648].
Lonergan KM, Iliopoulos O, Ohh M, ..., Kaelin W (1998) Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau
tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Molecular and Cellular Biology.
[IF=1.026, Cited=238, 9447969].
Lai A, Lee JM, Yang WM, ..., Branton PE (1999) RBP1 recruits both histone deacetylase-dependent and -independent
repression activities to retinoblastoma family proteins. Molecular and Cellular Biology. [IF=1.026, Cited=102, 10490602].
Adams PD, Li X, Sellers WR, ..., Kaelin W (1999) Retinoblastoma protein contains a C-terminal motif that targets it for
phosphorylation by cyclin-cdk complexes. Molecular and Cellular Biology. [IF=1.026, Cited=107, 9891042].
Zeng X, Chen L, Jost CA, ..., Lu H (1999) MDM2 suppresses p73 function without promoting p73 degradation. Molecular and
Cellular Biology. [IF=1.026, Cited=207, 10207051].
Koochekpour S, Jeffers M, Wang PH, ..., Vande Woude GF (1999) The von Hippel-Lindau tumor suppressor gene inhibits
hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Molecular
and Cellular Biology. [IF=1.026, Cited=123, 10454537].
Miyake S, Sellers WR, Safran M, ..., Kaelin W (2000) Cells degrade a novel inhibitor of differentiation with E1A-like
properties upon exiting the cell cycle. Molecular and Cellular Biology. [IF=1.026, Cited=76, 11073989].
Hansen WJ, Ohh M, Moslehi J, ..., Welch WJ (2002) Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL)
tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase
activity. Molecular and Cellular Biology. [IF=1.026, Cited=56, 11865071].
Stickle NH, Chung J, Klco JM, ..., Ohh M (2004) pVHL modification by NEDD8 is required for fibronectin matrix assembly
and suppression of tumor development. Molecular and Cellular Biology. [IF=1.026, Cited=118, 15060148].
Kaelin W, Ewen ME, Livingston DM (1990) Definition of the minimal simian virus 40 large T antigen- and adenovirus
E1A-binding domain in the retinoblastoma gene product. Molecular and Cellular Biology. [IF=1.026, Cited=121, 2162480].
Slansky JE, Li Y, Kaelin W, Farnham PJ (1993) A protein synthesis-dependent increase in E2F1 mRNA correlates with growth
regulation of the dihydrofolate reductase promoter. Molecular and Cellular Biology. [IF=1.026, Cited=179, 8441401].
Neuman E, Flemington EK, Sellers WR, Kaelin W (1994) Transcription of the E2F-1 gene is rendered cell cycle dependent by
E2F DNA-binding sites within its promoter. Molecular and Cellular Biology. [IF=1.026, Cited=164, 7935380].
Li Y, Slansky JE, Myers DJ, ..., Farnham PJ (1994) Cloning, chromosomal location, and characterization of mouse E2F1.
Molecular and Cellular Biology. [IF=1.026, Cited=41, 8114719].
Kaelin W (2005) Proline hydroxylation and gene expression. Annual Review of Biochemistry. [IF=5.273, Cited=289, 15952883].
Kaelin W (2007) Von Hippel-Lindau disease. Annual Review of Pathology: Mechanisms of Disease. [IF=6.626, Cited=205, 18039096].
Kaelin W, Kaelin WG, Sawyers C, ..., Mihich E (2007) Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical
investigation in cancer. Cancer Research. [IF=1.624, Cited=1, 18045966].
Kaelin W, Livingston D, Loda M, ..., Mihich E (2013) Twenty-fifth annual Pezcoller Symposium: Metabolism and
tumorigenesis. Cancer Research. [IF=1.624, Cited=0, 24097824].
Kaufman B, Scharf O, Arbeit J, ..., Ivy SP (2004) Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer
Research. [IF=1.624, Cited=20, 15126380].
Mihich E, Kaelin W (2004) Fifteenth annual Pezcoller symposium: molecular in vivo visualization of cancer cells. Cancer
Research. [IF=1.624, Cited=0, 15087414].
Avigan DE, Bukowski RM, Childs RW, ..., King L (2004) Innovations and challenges in renal cancer: consensus statement
from the first international conference. Clinical Cancer Research. [IF=2.156, Cited=21, 15448017].
Kaelin W (2007) The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clinical Cancer Research.
[IF=2.156, Cited=182, 17255293].
Choueiri TK, Albiges L, Bakouny Z, ..., Hammers HJ (2022) From Basic Science to Clinical Translation in Kidney Cancer: A
Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research. [IF=2.156, Cited=7, 34965942].
Kaelin W (2004) The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clinical Cancer Research. [IF=2.156,
Cited=172, 15448019].
Shen C, Beroukhim R, Schumacher SE, ..., Kaelin W (2011) Genetic and functional studies implicate HIF1α as a 14q kidney
cancer suppressor gene. Cancer Discovery. [IF=3.608, Cited=273, 22037472].
Oser MG, Fonseca R, Chakraborty AA, ..., Kaelin W (2018) Cells Lacking the RB1 Tumor Suppressor Gene Are
Hyperdependent on Aurora B Kinase for Survival. Cancer Discovery. [IF=3.608, Cited=85, 30373918].
Moslehi J, Minamishima YA, Shi J, ..., Kaelin W (2010) Loss of hypoxia-inducible factor prolyl hydroxylase activity in
cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. [IF=6.144, Cited=106, 20733101].
Wyant GA, Jiang Q, Singh M, ..., Kaelin W (2024) Induction of DEPP1 by HIF Mediates Multiple Hallmarks of Ischemic
Cardiomyopathy. Circulation. [IF=6.144, Cited=0, 38881449].
Kaelin W (1999) Taking aim at novel molecular targets in cancer therapy. Journal of Clinical Investigation. [IF=2.423,
Cited=3, 10587511].
Kaelin W (1999) Choosing anticancer drug targets in the postgenomic era. Journal of Clinical Investigation. [IF=2.423,
Cited=30, 10587513].
Minamishima YA, Moslehi J, Bardeesy N, ..., Kaelin W (2007) Somatic inactivation of the PHD2 prolyl hydroxylase causes
polycythemia and congestive heart failure. Blood. [IF=2.983, Cited=205, 18096761].
Querbes W, Bogorad RL, Moslehi J, ..., Kaelin W (2012) Treatment of erythropoietin deficiency in mice with systemically
administered siRNA. Blood. [IF=2.983, Cited=29, 22611156].
Kaelin W (2009) Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Medicine.
[IF=2.422, Cited=53, 19863774].
Kim WY, Kaelin W (2004) Role of VHL gene mutation in human cancer. Journal of Clinical Oncology. [IF=6.449, Cited=575, 15611513].
Zhang J, Wang C, Chen X, ..., Zhang Q (2015) EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial
function in breast cancer. EMBO Journal. [IF=2.114, Cited=51, 26492917].
Kaelin W (1997) Recent insights into the functions of the retinoblastoma susceptibility gene product. Cancer
Investigation. [IF=0.526, Cited=25, 9171859].
Kaelin W (2003) E2F1 as a target: promoter-driven suicide and small molecule modulators. Cancer Biology and Therapy.
[IF=0.866, Cited=0, 14508080].

Publication with MISMATCHING institution:

Kaelin W (2007) The von hippel-lindau tumor suppressor protein: an update. None. [IF=None, Cited=25, 17998064].
Zhang H, Christensen CL, Dries R, ..., Wong KK (2019) CDK7 Inhibition Potentiates Genome Instability Triggering Anti-
tumor Immunity in Small Cell Lung Cancer. Cancer Cell. [IF=5.274, Cited=93, 31883968].
Kaelin W, Ratcliffe PJ (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular
Cell. [IF=2.773, Cited=1000, 18498744].
Kaelin W, Maher ER (1998) The VHL tumour-suppressor gene paradigm. Trends in Genetics. [IF=2.117, Cited=121, 9820032].
Kaelin W (2005) The concept of synthetic lethality in the context of anticancer therapy. Nature Reviews Cancer.
[IF=10.357, Cited=828, 16110319].
Kaelin W (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nature Reviews Cancer.
[IF=10.357, Cited=448, 18923434].
Olenyuk BZ, Zhang GJ, Klco JM, ..., Dervan PB (2004) Inhibition of vascular endothelial growth factor with a sequence-
specific hypoxia response element antagonist. Proceedings of the National Academy of Sciences of the United States of
America. [IF=2.765, Cited=131, 15556999].
Safran M, Kim WY, O'Connell F, ..., Kaelin W (2005) Mouse model for noninvasive imaging of HIF prolyl hydroxylase
activity: assessment of an oral agent that stimulates erythropoietin production. Proceedings of the National Academy of
Sciences of the United States of America. [IF=2.765, Cited=201, 16373502].
Bommi-Reddy A, Almeciga I, Sawyer J, ..., Grueneberg DA (2008) Kinase requirements in human cells: III. Altered kinase
requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proceedings of the National Academy of
Sciences of the United States of America. [IF=2.765, Cited=91, 18948595].
Lin W, Cao J, Liu J, ..., Yan Q (2011) Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase
suppresses tumorigenesis in mice lacking Rb1 or Men1. Proceedings of the National Academy of Sciences of the United
States of America. [IF=2.765, Cited=99, 21788502].
Beshiri ML, Holmes KB, Richter WF, ..., Benevolenskaya EV (2012) Coordinated repression of cell cycle genes by KDM5A and
E2F4 during differentiation. Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765,
Cited=54, 23093672].
Ivan M, Haberberger T, Gervasi DC, ..., Kaelin W (2002) Biochemical purification and pharmacological inhibition of a
mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proceedings of the National Academy of Sciences of the
United States of America. [IF=2.765, Cited=352, 12351678].
Grafi G, Burnett RJ, Helentjaris T, ..., Kaelin W (1996) A maize cDNA encoding a member of the retinoblastoma protein
family: involvement in endoreduplication. Proceedings of the National Academy of Sciences of the United States of
America. [IF=2.765, Cited=131, 8799136].
Iliopoulos O, Ohh M, Kaelin W (1998) pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from
internal translation initiation. Proceedings of the National Academy of Sciences of the United States of America.
[IF=2.765, Cited=147, 9751722].
Ohh M, Kim WY, Moslehi JJ, ..., Kaelin W (2002) An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation
in mammalian cells. EMBO Reports. [IF=1.375, Cited=123, 11818338].
Kaelin W (2005) The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harbor
Symposia on Quantitative Biology. [IF=0.889, Cited=36, 16869749].
Sorrell AD, Lee S, Stolle C, ..., Weitzel JN (2011) Clinical and functional properties of novel VHL mutation (X214L)
consistent with Type 2A phenotype and low risk of renal cell carcinoma. Clinical Genetics. [IF=1.39, Cited=5, 20560986].
Beroukhim R, Brunet JP, Di Napoli A, ..., Signoretti S (2009) Patterns of gene expression and copy-number alterations in
von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Research. [IF=1.624,
Cited=269, 19470766].
Couvé S, Ladroue C, Laine E, ..., Gardie B (2014) Genetic evidence of a precisely tuned dysregulation in the hypoxia
signaling pathway during oncogenesis. Cancer Research. [IF=1.624, Cited=24, 25371412].
Ernstoff MS, Figlin RA, George DJ, ..., King L (2007) Innovations and challenges in renal cell carcinoma: summary
statement from the Second Cambridge Conference. Clinical Cancer Research. [IF=2.156, Cited=22, 17255291].
Andronesi OC, Loebel F, Bogner W, ..., Cahill DP (2015) Treatment Response Assessment in IDH-Mutant Glioma Patients by
Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research. [IF=2.156, Cited=86, 26534967].
Safran M, Kim WY, Kung AL, ..., Kaelin W (2003) Mouse reporter strain for noninvasive bioluminescent imaging of cells
that have undergone Cre-mediated recombination. Molecular Imaging. [IF=0.687, Cited=106, 14717328].
Sethi N, Kikuchi O, McFarland J, ..., Bass AJ (2019) Mutant p53 induces a hypoxia transcriptional program in gastric and
esophageal adenocarcinoma. JCI insight. [IF=1.554, Cited=16, 31391338].
Kaelin W (2018) HIF2 Inhibitor Joins the Kidney Cancer Armamentarium. Journal of Clinical Oncology. [IF=6.449,
Cited=13, 29384723].
Kaelin W (2017) The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. None. [IF=None, Cited=0, 28790514].
Kaelin W (2022) THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND
DRUGGING THE UNDRUGGABLE. None. [IF=None, Cited=0, 36196173].

Publication with MISSING institution:

Bukowski RM, Escudier BJ, Figlin RA, ..., King L (2009) Innovations and challenges in renal cancer: summary statement
from the Third Cambridge Conference. Cancer. [IF=2.097, Cited=13, 19402064].
Genbacev O, Krtolica A, Kaelin W, Fisher SJ (2001) Human cytotrophoblast expression of the von Hippel-Lindau protein is
downregulated during uterine invasion in situ and upregulated by hypoxia in vitro. Developmental Biology. [IF=0.815,
Cited=53, 11336512].
Kondo K, Kaelin W (2001) The von Hippel-Lindau tumor suppressor gene. Experimental Cell Research. [IF=0.736, Cited=112, 11237528].
Adams PD, Kaelin W (1995) Transcriptional control by E2F. Seminars in Cancer Biology. [IF=2.556, Cited=73, 7647312].
Jost CA, Ginsberg D, Kaelin W (1996) A conserved region of unknown function participates in the recognition of E2F
family members by the adenovirus E4 ORF 6/7 protein. Virology. [IF=0.835, Cited=13, 8659131].
Adams PD, Kaelin W (1996) The cellular effects of E2F overexpression. None. [IF=None, Cited=63, 8575214].
Petronis JD, LaFrance ND, Kaelin W (1985) Lymphoscintigraphy. None. [IF=None, Cited=1, 3896815].
Rogers LR, LoRusso P, Nadler P, ..., Kaelin W (2010) Erlotinib therapy for central nervous system hemangioblastomatosis
associated with von Hippel-Lindau disease: a case report. Journal of Neuro-Oncology. [IF=1.338, Cited=18, 20524042].
Kaelin W, Spivak JL (1986) Systemic lupus erythematosus and myelofibrosis. American Journal of Medicine. [IF=1.05,
Cited=23, 3777001].
Chittenden T, Livingston DM, Kaelin W (1991) The T/E1A-binding domain of the retinoblastoma product can interact
selectively with a sequence-specific DNA-binding protein. Cell. [IF=8.479, Cited=240, 1828394].
Krek W, Ewen ME, Shirodkar S, ..., Livingston DM (1994) Negative regulation of the growth-promoting transcription factor
E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell. [IF=8.479, Cited=275, 8033208].
Sellers WR, Kaelin W (1996) RB [corrected] as a modulator of transcription. None. [IF=None, Cited=29, 8764839].
Neuman E, Sellers WR, McNeil JA, ..., Kaelin W (1996) Structure and partial genomic sequence of the human E2F1 gene.
Gene. [IF=0.932, Cited=15, 8964493].
Yang H, Ivan M, Min JH, ..., Kaelin W (2004) Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of
oxygen sensing. None. [IF=None, Cited=8, 15063684].
Zhang GJ, Kaelin W (2005) Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through
changes in p27 turnover. None. [IF=None, Cited=5, 16338380].
Brugarolas J, Kaelin W (2004) Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes.
Cancer Cell. [IF=5.274, Cited=107, 15261137].
Wei W, Jin J, Schlisio S, ..., Kaelin W (2005) The v-Jun point mutation allows c-Jun to escape GSK3-dependent
recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. [IF=5.274, Cited=302, 16023596].
Lee S, Nakamura E, Yang H, ..., Schlisio S (2005) Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial
pheochromocytoma genes: developmental culling and cancer. Cancer Cell. [IF=5.274, Cited=338, 16098468].
Zhang Q, Gu J, Li L, ..., Bommi-Reddy A (2009) Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl
hydroxylase. Cancer Cell. [IF=5.274, Cited=96, 19878873].
Loda M, Kaelin W (2010) Prostate cancer: beta control your hormones. Cancer Cell. [IF=5.274, Cited=4, 20385354].
Inuzuka H, Tseng A, Gao D, ..., Wei W (2010) Phosphorylation by casein kinase I promotes the turnover of the Mdm2
oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell. [IF=5.274, Cited=147, 20708156].
Gan B, Lim C, Chu G, ..., DePinho RA (2010) FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal
tumorigenesis. Cancer Cell. [IF=5.274, Cited=105, 21075312].
Klose RJ, Yan Q, Tothova Z, ..., Kaelin W (2007) The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell.
[IF=8.479, Cited=297, 17320163].
Olenchock BA, Moslehi J, Baik AH, ..., Kaelin W (2016) EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for
Remote Ischemic Protection. Cell. [IF=8.479, Cited=18, 27058668].
Li L, Kaelin W (2011) New insights into the biology of renal cell carcinoma. Hematology/Oncology Clinics of North
America. [IF=1.055, Cited=47, 21763962].
Benevolenskaya EV, Murray HL, Branton P, ..., Kaelin W (2005) Binding of pRB to the PHD protein RBP2 promotes cellular
differentiation. Molecular Cell. [IF=2.773, Cited=167, 15949438].
Yang H, Minamishima YA, Yan Q, ..., Kaelin W (2007) pVHL acts as an adaptor to promote the inhibitory phosphorylation of
the NF-kappaB agonist Card9 by CK2. Molecular Cell. [IF=2.773, Cited=120, 17936701].
van Oevelen C, Wang J, Asp P, ..., Dynlacht BD (2008) A role for mammalian Sin3 in permanent gene silencing. Molecular
Cell. [IF=2.773, Cited=94, 18995834].
Shen C, Kaelin W (2012) The VHL/HIF axis in clear cell renal carcinoma. Seminars in Cancer Biology. [IF=2.556,
Cited=230, 22705278].
Corless CL, Kibel AS, Iliopoulos O, Kaelin W (1997) Immunostaining of the von Hippel-Lindau gene product in normal and
neoplastic human tissues. Human Pathology. [IF=1.137, Cited=65, 9104946].
Adams PD, Lopez P, Sellers WR, Kaelin W (1997) Fluorescence-activated cell sorting of transfected cells. None. [IF=None,
Cited=5, 9251011].
Field SJ, Tsai FY, Kuo F, ..., Greenberg ME (1996) E2F-1 functions in mice to promote apoptosis and suppress
proliferation. Cell. [IF=8.479, Cited=472, 8653790].
Aiello LP, George DJ, Cahill MT, ..., Kaelin W (2002) Rapid and durable recovery of visual function in a patient with
von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
Ophthalmology. [IF=4.3, Cited=72, 12208726].
Marin MC, Kaelin W (2000) p63 and p73: old members of a new family. None. [IF=None, Cited=26, 10799748].
Adams PD, Kaelin W (1998) Negative control elements of the cell cycle in human tumors. Current Opinion in Cell Biology.
[IF=1.539, Cited=20, 9914179].
Ivan M, Kaelin W (2001) The von Hippel-Lindau tumor suppressor protein. Current Opinion in Genetics and Development.
[IF=0.801, Cited=117, 11163147].
Kim W, Kaelin W (2003) The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
Current Opinion in Genetics and Development. [IF=0.801, Cited=110, 12573436].
Ohh M, Yauch RL, Lonergan KM, ..., Iliopoulos O (1998) The von Hippel-Lindau tumor suppressor protein is required for
proper assembly of an extracellular fibronectin matrix. Molecular Cell. [IF=2.773, Cited=263, 9651579].
Ohh M, Kaelin W (1999) The von Hippel-Lindau tumour suppressor protein: new perspectives. None. [IF=None, Cited=41, 10366821].
Reddy A, Kaelin W (2002) Using cancer genetics to guide the selection of anticancer drug targets. Current Opinion in
Pharmacology. [IF=0.854, Cited=23, 12127868].
Kondo K, Klco J, Nakamura E, ..., Kaelin W (2002) Inhibition of HIF is necessary for tumor suppression by the von
Hippel-Lindau protein. Cancer Cell. [IF=5.274, Cited=500, 12086860].
Irwin MS, Kondo K, Marin MC, ..., Kaelin W (2003) Chemosensitivity linked to p73 function. Cancer Cell. [IF=5.274,
Cited=281, 12726865].
Brugarolas JB, Vazquez F, Reddy A, ..., Kaelin W (2003) TSC2 regulates VEGF through mTOR-dependent and -independent
pathways. Cancer Cell. [IF=5.274, Cited=353, 12957289].
Irwin MS, Kaelin W (2001) Role of the newer p53 family proteins in malignancy. Apoptosis : an international journal on
programmed cell death. [IF=1.287, Cited=44, 11321038].
Kaelin W (1999) Cancer. Many vessels, faulty gene. Nature. [IF=11.591, Cited=27, 10353237].
Gong JG, Costanzo A, Yang HQ, ..., Wang JY (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to
cisplatin-induced DNA damage. Nature. [IF=11.591, Cited=588, 10391249].
Ohh M, Park CW, Ivan M, ..., Kaelin W (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the
beta-domain of the von Hippel-Lindau protein. Nature Cell Biology. [IF=3.908, Cited=938, 10878807].
Lissy NA, Davis PK, Irwin M, ..., Dowdy SF (2000) A common E2F-1 and p73 pathway mediates cell death induced by TCR
activation. Nature. [IF=11.591, Cited=198, 11034214].
Irwin M, Marin MC, Phillips AC, ..., Kaelin W (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature.
[IF=11.591, Cited=384, 11034215].
Jost CA, Marin MC, Kaelin W (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis.
Nature. [IF=11.591, Cited=611, 9296498].
Kaelin W (2006) Cell biology: divining cancer cell weaknesses. Nature. [IF=11.591, Cited=2, 16672958].
Kaelin W, Thompson CB (2010) Q&A: Cancer: clues from cell metabolism. Nature. [IF=11.591, Cited=105, 20520704].
Kaelin W (2017) Publish houses of brick, not mansions of straw. Nature. [IF=11.591, Cited=17, 28541345].
Marin MC, Jost CA, Brooks LA, ..., Kaelin W (2000) A common polymorphism acts as an intragenic modifier of mutant p53
behaviour. Nature Genetics. [IF=6.89, Cited=325, 10802655].
Kung AL, Wang S, Klco JM, ..., Livingston DM (2000) Suppression of tumor growth through disruption of hypoxia-inducible
transcription. Nature Medicine. [IF=11.877, Cited=298, 11100117].
Livingston DM, Kaelin W, Chittenden T, Qin X (1993) Structural and functional contributions to the G1 blocking action of
the retinoblastoma protein. (the 1992 Gordon Hamilton Fairley Memorial Lecture). British Journal of Cancer. [IF=1.928,
Cited=10, 8347480].
Bommi-Reddy A, Kaelin W (2010) Slaying RAS with a synthetic lethal weapon. Cell Research. [IF=3.826, Cited=6, 20118966].
Wei W, Ayad NG, Wan Y, ..., Kaelin W (2004) Degradation of the SCF component Skp2 in cell-cycle phase G1 by the
anaphase-promoting complex. Nature. [IF=11.591, Cited=315, 15014503].
Koivunen P, Lee S, Duncan CG, ..., Kaelin W (2012) Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to
EGLN activation. Nature. [IF=11.591, Cited=491, 22343896].
Binné UK, Classon MK, Dick FA, ..., Dyson NJ (2006) Retinoblastoma protein and anaphase-promoting complex physically
interact and functionally cooperate during cell-cycle exit. Nature Cell Biology. [IF=3.908, Cited=118, 17187060].
Young AP, Schlisio S, Minamishima YA, ..., Kaelin W (2008) VHL loss actuates a HIF-independent senescence programme
mediated by Rb and p400. Nature Cell Biology. [IF=3.908, Cited=158, 18297059].
Iliopoulos O, Kibel A, Gray S, Kaelin W (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nature
Medicine. [IF=11.877, Cited=405, 7585187].
Zhang GJ, Safran M, Wei W, ..., Kaelin W (2004) Bioluminescent imaging of Cdk2 inhibition in vivo. Nature Medicine.
[IF=11.877, Cited=56, 15122251].
Parr MJ, Manome Y, Tanaka T, ..., Fine HA (1997) Tumor-selective transgene expression in vivo mediated by an
E2F-responsive adenoviral vector. Nature Medicine. [IF=11.877, Cited=74, 9334729].
Kim WY, Safran M, Buckley MRM, ..., Kaelin W (2006) Failure to prolyl hydroxylate hypoxia-inducible factor alpha
phenocopies VHL inactivation in vivo. EMBO Journal. [IF=2.114, Cited=168, 16977322].
Seelan RS, Irwin M, van der Stoop P, ..., Liu W (2002) The human p73 promoter: characterization and identification of
functional E2F binding sites. Neoplasia. [IF=1.035, Cited=34, 11988839].
Siegert JL, Rushton JJ, Sellers WR, ..., Robbins PD (2000) Cyclin D1 suppresses retinoblastoma protein-mediated
inhibition of TAFII250 kinase activity. Oncogene. [IF=1.523, Cited=12, 11126356].
Kim WY, Kaelin W (2006) Molecular pathways in renal cell carcinoma--rationale for targeted treatment. Seminars in
Oncology. [IF=1.319, Cited=37, 17045088].
George DJ, Kaelin W (2003) The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. New
England Journal of Medicine. [IF=17.194, Cited=91, 12890838].
Walling DM, Kaelin W (1991) Pyomyositis in patients with diabetes mellitus. None. [IF=None, Cited=32, 1962087].
Hoffman MA, Ohh M, Yang H, ..., Kaelin W (2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve
the ability to downregulate HIF. Human Molecular Genetics. [IF=1.158, Cited=233, 11331612].
Maher ER, Kaelin W (1997) von Hippel-Lindau disease. Medicine (United States). [IF=0.799, Cited=283, 9413424].
Sellers WR, Novitch BG, Miyake S, ..., Kaelin W (1998) Stable binding to E2F is not required for the retinoblastoma
protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes and Development.
[IF=1.985, Cited=217, 9420334].
Kamura T, Sato S, Haque D, ..., Conaway JW (1998) The Elongin BC complex interacts with the conserved SOCS-box motif
present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes and Development. [IF=1.985,
Cited=353, 9869640].
Brugarolas J, Lei K, Hurley RL, ..., Kaelin W (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the
TSC1/TSC2 tumor suppressor complex. Genes and Development. [IF=1.985, Cited=868, 15545625].
Schlisio S, Kenchappa RS, Vredeveld LCW, ..., Kaelin W (2008) The kinesin KIF1Bbeta acts downstream from EglN3 to induce
apoptosis and is a potential 1p36 tumor suppressor. Genes and Development. [IF=1.985, Cited=215, 18334619].
Losman JA, Kaelin W (2013) What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes and
Development. [IF=1.985, Cited=379, 23630074].
Akbay EA, Moslehi J, Christensen CL, ..., Wong KK (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes
cardiomyopathy and neurodegeneration in mice. Genes and Development. [IF=1.985, Cited=53, 24589777].
Qin XQ, Chittenden T, Livingston DM, Kaelin W (1992) Identification of a growth suppression domain within the
retinoblastoma gene product. Genes and Development. [IF=1.985, Cited=264, 1534305].
O'Hagan RC, Ohh M, David G, ..., DePinho RA (2000) Myc-enhanced expression of Cul1 promotes ubiquitin-dependent
proteolysis and cell cycle progression. Genes and Development. [IF=1.985, Cited=131, 10970882].
Querido E, Blanchette P, Yan Q, ..., Branton PE (2001) Degradation of p53 by adenovirus E4orf6 and E1B55K proteins
occurs via a novel mechanism involving a Cullin-containing complex. Genes and Development. [IF=1.985, Cited=335, 11731475].
Serebriiskii IG, Mitina O, Pugacheva EN, ..., Golemis EA (2002) Detection of peptides, proteins, and drugs that
selectively interact with protein targets. Genome Research. [IF=1.745, Cited=19, 12421766].
Chittenden T, Livingston DM, Kaelin W (1991) RB associates with an E2F-like, sequence-specific DNA-binding protein. Cold
Spring Harbor Symposia on Quantitative Biology. [IF=0.889, Cited=11, 1819485].
Ivan M, Kondo K, Yang H, ..., Kaelin W (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation:
implications for O2 sensing. Science. [IF=7.729, Cited=1000, 11292862].
Neuman E, Flemington EK, Sellers WR, Kaelin W (1995) Transcription of the E2F-1 gene is rendered cell cycle dependent by
E2F DNA-binding sites within its promoter. Molecular and Cellular Biology. [IF=1.026, Cited=7, 7623859].
Kaelin W (2022) Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. Journal of
Clinical Investigation. [IF=2.423, Cited=30, 36106637].
Safran M, Kaelin W (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. Journal of Clinical Investigation.
[IF=2.423, Cited=207, 12639980].
Wei W, Kaelin W (2011) Good COP1 or bad COP1? In vivo veritas. Journal of Clinical Investigation. [IF=2.423, Cited=22, 21403396].
Ohh M, Takagi Y, Aso T, ..., Kaelin W (1999) Synthetic peptides define critical contacts between elongin C, elongin B,
and the von Hippel-Lindau protein. Journal of Clinical Investigation. [IF=2.423, Cited=62, 10587522].
Kim WY, Perera S, Zhou B, ..., Wong KK (2009) HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.
Journal of Clinical Investigation. [IF=2.423, Cited=100, 19662677].
Sellers WR, Kaelin W (1997) Role of the retinoblastoma protein in the pathogenesis of human cancer. Journal of Clinical
Oncology. [IF=6.449, Cited=137, 9363859].
Kondo K, Kim WY, Lechpammer M, Kaelin W (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor
growth. PLoS Biology. [IF=2.285, Cited=377, 14691554].
Ohh M, Kaelin W (2003) VHL and kidney cancer. Methods in Molecular Biology. [IF=0.413, Cited=17, 12710686].
Nakamura E, Kaelin W (2006) Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma.
Endocrine Pathology. [IF=1.06, Cited=21, 17159241].
Astuti D, Ricketts CJ, Chowdhury R, ..., Maher ER (2010) Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in
individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. None. [IF=None, Cited=35, 20959442].
Nakamura E, Abreu-e-Lima P, Awakura Y, ..., Kaelin W (2006) Clusterin is a secreted marker for a hypoxia-inducible
factor-independent function of the von Hippel-Lindau tumor suppressor protein. American Journal of Pathology. [IF=1.235,
Cited=42, 16436671].
Young AP, Kaelin W (2008) Senescence triggered by the loss of the VHL tumor suppressor. Cell Cycle. [IF=0.792, Cited=9, 18583945].
Zbar B, Kaelin W, Maher E, Richard S (1999) Third International Meeting on von Hippel-Lindau disease. Cancer Research.
[IF=1.624, Cited=0, 10232616].
Brooks LA, Tidy JA, Gusterson B, ..., Crook T (2000) Preferential retention of codon 72 arginine p53 in squamous cell
carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Research. [IF=1.624,
Cited=0, 11156383].
Irwin MS, Kaelin W (2001) p53 family update: p73 and p63 develop their own identities. None. [IF=None, Cited=0, 11457731].
Yang H, Kaelin W (2001) Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for
oxygen sensing. None. [IF=None, Cited=0, 11571227].
Jiang Y, Zhang W, Kondo K, ..., Nacht M (2003) Gene expression profiling in a renal cell carcinoma cell line: dissecting
VHL and hypoxia-dependent pathways. Molecular Cancer Research. [IF=1.012, Cited=0, 12692265].
Kaelin W, Shrivastav S, Jirtle RL (1984) Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing
rats following intravenous flunarizine. Cancer Research. [IF=1.624, Cited=0, 6692410].
Shrivastav S, Kaelin W, Joines WT, Jirtle RL (1983) Microwave hyperthermia and its effect on tumor blood flow in rats.
Cancer Research. [IF=1.624, Cited=0, 6883324].
Kaelin W, Shrivastav S, Shand DG, Jirtle RL (1982) Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-
bearing rats. Cancer Research. [IF=1.624, Cited=0, 7104994].
Los M, Jansen GH, Kaelin W, ..., Voest EE (1996) Expression pattern of the von Hippel-Lindau protein in human tissues.
Laboratory Investigation. [IF=1.175, Cited=0, 8765323].
Iliopoulos O, Kaelin W (1997) The molecular basis of von Hippel-Lindau disease. Molecular Medicine. [IF=1.026, Cited=0, 9205944].
Lieubeau-Teillet B, Rak J, Jothy S, ..., Kerbel RS (1998) von Hippel-Lindau gene-mediated growth suppression and
induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Research.
[IF=1.624, Cited=0, 9810005].